you've said it all along, higher risk reward ratio with ipci, and I would have to agree. even just a little clarity from odidi would help, but he fails to inform or reassure investors. why aren't any of the ANDAs being approved? many other co's generics have been approved. what is really going on and why?
one good thing samsa is that you can trade this in your ROTH without wash sale consequences. so, maybe you can trade your way out upon any strength. imo you've become too personally attached and should sell 1/2 of your position and buy GILD here in the $90s. there are just so many good opportunities right now in biotech; why waste the risk on ipci's potential when you can buy quality stocks at a discount? jmo
to be honest, even I am surprised by lack of leadership and accountability. to put a spin on samsa's vocabulary, the teva deal was a specious press release imho. the purchase of real estate was also specious, as it added more debt and liabilities to the sheet and was not in the better interest of shareholders imo.
"If fixed medium or high doses are used, buprenorphine and methadone appear no different in effectiveness (retention in treatment and suppression of illicit opioid use); however, fixed doses are rarely used in clinical practice so the flexible dose results are more relevant to patient care. Methadone is superior to buprenorphine in retaining people in treatment, and methadone equally suppresses illicit opioid use."